Adjuvant Chemotherapy in Bladder Cancer

1. Intravesical Adjuvant Chemo

For non-muscle-invasive bladder cancer (NMIBC).
Drugs: Mitomycin C (MMC), Gemcitabine, Epirubicin.
Administration: Directly into the bladder via catheter.
When Used?
- Single dose within 24 hours of TURBT (lowers recurrence by ~40%).
- Weekly instillations for 6–8 weeks (intermediate-risk tumors).

2. Systemic Adjuvant Chemo

For muscle-invasive bladder cancer (MIBC) after cystectomy.
Drugs: Cisplatin-based combinations (e.g., MVAC, GemCis).
Goal: Prevent distant metastasis if high-risk features (e.g., lymph node involvement).

How It Works

Disrupts cancer cell DNA (alkylating agents, antimetabolites).
Targets rapidly dividing cells (prevents residual tumors from growing).

Effectiveness

Cancer Type	Adjuvant Chemo Benefit
NMIBC	20–30% lower recurrence with intravesical MMC.
MIBC (post-cystectomy)	5–10% survival improvement with cisplatin-based chemo.

Side Effects

Type	Common Side Effects
Intravesical	Bladder irritation, UTI-like symptoms.
Systemic	Nausea, fatigue, low blood counts, neuropathy.

Who Needs It?

NMIBC: Intermediate/high-risk tumors (multifocal, high-grade).
MIBC: Positive lymph nodes, extravesical extension.

Contraindications: Severe kidney disease (cisplatin), poor performance status.

Alternatives

Immunotherapy (e.g., Pembrolizumab) for cisplatin-ineligible MIBC.
BCG (for NMIBC) if chemo fails or high-risk features.

Takeaway

Adjuvant chemo is a proactive strike against hidden cancer cells. For bladder cancer, it’s given in the bladder (intravesical) for NMIBC or systemically (IV) for MIBC after surgery.